Serotonin–to–dopamine transporter ratios in Parkinson’s dyskinesias: the longitudinal study
Objective: This study was designed to detect whether in Parkinson’s disease (PD) the putaminal serotonin–over–dopamine transporter ratio has a threshold that is critical for the…Longitudinal AV-1451 PET imaging in Progressive Supranuclear Palsy and Cortico-Basal Syndrome
Objective: To evaluate change in AV-1451 positron emission tomography (PET) imaging in patients with Progressive Supranuclear Palsy (PSP) and Cortico-Basal Syndrome (CBS) over 9 months…18F-AV-1451 PET imaging in pre-dementia Parkinson’s disease
Objective: To describe cortical and subcortical 18F-AV-1451 binding in Parkinson’s disease patients with and without mild cognitive impairment (PD-MCI and PD-nonMCI). Background: The radioligand 18F-AV-1451…Loss of PDE10A expression in patients with PDE10A and ADYC5 mutations
Objective: To assess phosphodiesterase 10A (PDE10A) expression in vivo, using [11C]IMA107 PET in patients with PDE10A and adenylate cyclase 5 (ADYC5) mutations. Background: Cyclic adenosine…Serotonergic, Dopaminergic Disruptions and Related Non-Motor Features Throughout the Course of Parkinson’s Disease: A Transversal PET Study
Objective: To explore the progression of DA and 5-HT lesions during the course of Parkinson’s disease (PD) and their respective contribution to the pathogenesis of…Neuroimaging studies in familial forms of Parkinson’s disease: A systematic review
Objective: We aim to systematically review the current status of MRI, PET and SPECT imaging in asymptomatic (aPD) and symptomatic (sPD) genetic carriers of PD.…In vivo mapping of nigro-striatal dopamine transporter (DAT) availability in early Parkinson´s disease patients using [18F]FE-PE2I and high-resolution positron emission tomography.
Objective: The objective of the present work was to evaluate in vivo with high resolution positron emission tomography (PET), the relative loss of the dopamine…[11C]PK11195 PET in Alzheimer’s disease and progressive supranuclear palsy: the NIMROD study
Objective: Here we test whether the intensity and regional distribution of neuro-inflammation differs between Alzheimer's disease (AD), Progressive Supranuclear Palsy (PSP) and controls; and whether neuro-inflammation…Absence of depression in de novo Parkinson’s disease: a benign motor phenotype?
Objective: This study aimed to assess the impact of early depression on motor deficits relative to the level of striatal dopaminergic depletion in patients with…Brain PET metabolic substrate of Impulse Control Disorders in Parkinson’s Disease
Objective: The aim of this study was to describe the cerebral metabolic PET substrate and related connectivity changes in Parkinson's disease patients with impulse control…
- « Previous Page
- 1
- …
- 28
- 29
- 30
- 31
- 32
- …
- 35
- Next Page »
